Ask AI
ProCE Banner Activity

BRUIN CLL-314: Pirtobrutinib vs Ibrutinib in Treatment-Naive and BTKi-Naive R/R CLL/SLL

Conference Coverage
Slideset

In the phase III BRUIN CLL-314 trial that enrolled treatment-naive and previously treated BTKi-naive patients with CLL/SLL, pirtobrutinib demonstrated a noninferior overall response rate compared with ibrutinib in the intention-to-treat and relapsed/ refractory populations with early evidence of higher ORR and prolonged PFS in treatment-naïve patients

Released: December 18, 2025

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from Lilly.

Lilly

Target Audience

This activity is intended for hematologists, oncologists, and other healthcare professionals caring for patients with relapsed/refractory CLL globally.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply recently presented data to clinical practice to expand treatment options and enhance outcomes for patients with relapsed/refractory CLL

  • Appraise the potential clinical implications of new data on novel targeted and cellular therapies for treatment selection and sequencing in patients with relapsed/refractory CLL

  • Support effective shared decision-making through patient education and resources on the potential clinical implications of recently presented data for relapsed/refractory CLL